Department of Pathology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado.
Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado - Anschutz Medical Campus, Aurora, Colorado.
Cancer Res. 2021 Jun 1;81(11):2833-2846. doi: 10.1158/0008-5472.CAN-20-3095. Epub 2021 Mar 9.
The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression. To determine the mechanisms underlying these relationships, we profiled AR-expressing human bladder cancer cells by AR chromatin immunoprecipitation sequencing and complementary transcriptomic approaches in response to stimulation by the synthetic androgen R1881. functional genomics consisting of pooled shRNA or pooled open reading frame libraries was employed to evaluate 97 genes that recapitulate the direction of expression associated with androgen stimulation. Interestingly, we identified CD44, the receptor for hyaluronic acid, a potent biomarker and driver of progressive disease in multiple tumor types, as significantly associated with androgen stimulation. CRISPR-based mutagenesis of androgen response elements associated with CD44 identified a novel silencer element leading to the direct transcriptional repression of CD44 expression. In human patients with bladder cancer, tumor AR and CD44 mRNA and protein expression were inversely correlated, suggesting a clinically relevant AR-CD44 axis. Collectively, our work describes a novel mechanism partly explaining the inverse relationship between AR and bladder cancer tumor progression and suggests that AR and CD44 expression may be useful for prognostication and therapeutic selection in primary bladder cancer. SIGNIFICANCE: This study describes novel AREs that suppress CD44 and an expected inverse correlation of AR-CD44 expression observed in human bladder tumors.
雄激素受体 (AR) 在实验性和人类膀胱癌的发展中都很重要。然而,AR 在膀胱癌生长和进展中的作用尚不清楚,文献表明,更晚期和更高级别的疾病与 AR 表达减少有关。为了确定这些关系的机制,我们通过 AR 染色质免疫沉淀测序和互补转录组学方法对表达 AR 的人膀胱癌细胞进行了分析,以响应合成雄激素 R1881 的刺激。采用功能基因组学方法,包括 pooled shRNA 或 pooled open reading frame libraries,评估了 97 个基因,这些基因的表达方向与雄激素刺激相关。有趣的是,我们发现了 CD44,它是透明质酸的受体,是多种肿瘤类型中具有强大生物标志物和进展性疾病驱动作用的因子,与雄激素刺激显著相关。与 CD44 相关的雄激素反应元件的 CRISPR 诱变确定了一个新的沉默元件,导致 CD44 表达的直接转录抑制。在患有膀胱癌的人类患者中,肿瘤 AR 和 CD44 mRNA 和蛋白表达呈负相关,提示存在临床相关的 AR-CD44 轴。总的来说,我们的工作描述了一种新的机制,部分解释了 AR 与膀胱癌肿瘤进展之间的反比关系,并表明 AR 和 CD44 表达可能对原发性膀胱癌的预后和治疗选择有用。意义:本研究描述了抑制 CD44 的新型 ARE 以及在人类膀胱癌中观察到的预期的 AR-CD44 表达的反比关系。
Cancer Res. 2021-6-1
Ann Surg Oncol. 2018-8-20
Biol Sex Differ. 2025-5-13
Cancers (Basel). 2024-3-18
Cancers (Basel). 2024-2-10
Front Pharmacol. 2024-1-12
Nat Rev Urol. 2020-5
CA Cancer J Clin. 2020-1-8
Curr Opin Urol. 2019-5